BIONOMICS LTD-ADR (BNOX) Stock Price, Forecast & Analysis
USA - NASDAQ:BNOX - US09063M2052 - ADR
BNOX Key Statistics, Chart & Performance
The current stock price of BNOX is 0.2531 USD. In the past month the price decreased by -14.09%. In the past year, price decreased by -82.9%.
BNOX Latest News, Press Relases and Analysis
BNOX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.03 | 384.47B | ||
| AMGN | AMGEN INC | 14.46 | 170.21B | ||
| GILD | GILEAD SCIENCES INC | 15.09 | 153.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.98 | 106.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.52 | 69.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 859.49 | 57.46B | ||
| ARGX | ARGENX SE - ADR | 62.1 | 51.27B | ||
| INSM | INSMED INC | N/A | 39.41B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.54 | 37.62B | ||
| NTRA | NATERA INC | N/A | 27.14B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.78B | ||
| BIIB | BIOGEN INC | 9.26 | 22.73B |
Related stock screener links
About BNOX
Company Profile
Bionomics Ltd is a AU-based company operating in Biotechnology industry. Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. The firm is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. The company is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. The company is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Its α7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. The Company’s CNS pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels.
Company Info
BIONOMICS LTD-ADR
200 Greenhill Road
Thebarton SOUTH AUSTRALIA AU
Employees: 8
Phone: 61881507400
BIONOMICS LTD-ADR / BNOX FAQ
Can you describe the business of BIONOMICS LTD-ADR?
Bionomics Ltd is a AU-based company operating in Biotechnology industry. Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. The firm is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. The company is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. The company is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Its α7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. The Company’s CNS pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels.
Can you provide the latest stock price for BIONOMICS LTD-ADR?
The current stock price of BNOX is 0.2531 USD. The price increased by 4.2% in the last trading session.
Does BIONOMICS LTD-ADR pay dividends?
BNOX does not pay a dividend.
How is the ChartMill rating for BIONOMICS LTD-ADR?
BNOX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is BIONOMICS LTD-ADR worth?
BIONOMICS LTD-ADR (BNOX) has a market capitalization of 4.94M USD. This makes BNOX a Nano Cap stock.
BNOX Technical Analysis
BNOX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BNOX. BNOX may be in some trouble as it scores bad on both profitability and health.
BNOX Financial Highlights
Over the last trailing twelve months BNOX reported a non-GAAP Earnings per Share(EPS) of -3.12. The EPS decreased by -115.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -131.15% | ||
| ROE | -175.51% | ||
| Debt/Equity | 0.05 |
BNOX Forecast & Estimates
For the next year, analysts expect an EPS growth of 33.83% and a revenue growth -80.75% for BNOX